Artelo Biosciences, Inc. (ARTL)
| Previous close | 1.3500 |
| Open | 1.3890 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.2915 - 1.3899 |
| 52-week range | 1.1500 - 2.9800 |
| Volume | |
| Avg. volume | 14,782 |
| Market cap | 4.325M |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
SOLANA BEACH, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that it will be participating in the 2024 Pharma Partnering Summit being held May 14th – 15th in San Diego, California. Gregory D. Gorgas, President and Chief Executive Officer of Artelo, is scheduled
- GlobeNewswire
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious ConditionsSOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, and neurological conditions, today announced the publication of an article, “The emerging role of fatty a
- GlobeNewswire
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that Gregory D. Gorgas, President and Chief Executive Officer of Artelo, will be a featured guest on the Benzinga All Access show. Mr. Gorgas is scheduled to appear on Tuesday, April 23, 2024, at ap
